ReviewHuman vaccines & immunotherapeutics2012
Glycoconjugate vaccine strategies for protection against invasive Salmonella infections.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Immunogenicity of a Bivalent Typhoid-Paratyphoid Conjugate Vaccine Against Diverse Salmonella Paratyphi A Isolates.The Journal of infectious diseases · 2026Trial
- Critical Roles of O-Acetylation Revealed by Synthetic Trisaccharide Antigens for a Broad-Spectrum Anti-Salmonella Vaccine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Synthesis and immunological evaluation of the lipopolysaccharide outer core ofChemical science · 2025Article
- Foodborne Infections andVaccines · 2024Review
- Synthesis ofThe Journal of organic chemistry · 2024Article
- Typhoid & paratyphoid vaccine development in the laboratory: a review & in-country experience.The Indian journal of medical research · 2024Review
- Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity.NPJ vaccines · 2024Article
- The role of tissue resident memory CD4 T cells in Salmonella infection: Implications for future vaccines.Vaccine · 2023Review
- A candidate glycoconjugate vaccine induces protective antibodies in the serum and intestinal secretions, antibody recall response and memory T cells and protects against both typhoidal and non-typhoidalFrontiers in immunology · 2023Article
- Article
- Syntheses of Salmonella Paratyphi A Associated Oligosaccharide Antigens and Development towards Anti-Paratyphoid Fever Vaccines.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- AttenuatedVirulence · 2019Article
- Immunogenicity and protective efficacy againstHuman vaccines & immunotherapeutics · 2019Article
- Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidalProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice.PLoS neglected tropical diseases · 2018Article
- Article
- Recombinant attenuated Salmonella Typhimurium with heterologous expression of the Salmonella Choleraesuis O-polysaccharide: high immunogenicity and protection.Scientific reports · 2017Article
- Conformational Preference of Serogroup B Salmonella O Polysaccharide in Presence and Absence of the Monoclonal Antibody Se155-4.The journal of physical chemistry. B · 2017Article
- Development of a glycoconjugate vaccine to prevent invasive Salmonella Typhimurium infections in sub-Saharan Africa.PLoS neglected tropical diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Salmonella enterica serovars Typhi and Paratyphi A and B and certain non-typhoidal Salmonella enterica (NTS) serovars are important causes of invasive Salmonella disease worldwide. NTS serovars Typhimurium and Enteritidis typically cause gastroenteritis in healthy children and adults in industrialized countries but in certain hosts (e.g., young infants, the elderly, immunocompromised individuals) they also cause invasive infections. These two serovars also cause invasive disease in infants and young children in sub-Saharan Africa. Whereas Salmonella surface polysaccharides are poor immunogens in animal models and do not generate immunologic memory, conjugation with carrier proteins overcomes these limitations. S. Typhi expresses a Vi polysaccharide capsule; Vi either alone or as a glycoconjugate protects humans from typhoid fever. In contrast, S. Paratyphi A and B and NTS (with rare exceptions) do not express capsular polysaccharides. Rather, their surface polysaccharides are the O polysaccharide (OPS) of lipopolysaccharide. In animal studies, immunization with Salmonella COPS (core polysaccharide-OPS) conjugated with carrier proteins generates functional immunity and protects against fatal Salmonella challenge. Conjugating to Salmonella proteins (flagellin, porins) may extend immune responses to another relevant target for antibody generation and enhance the glyconjugate's efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.